The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; GlaxoSmithKline; Halozyme; Histosonics; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics; Rafael Pharmaceuticals
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen
 
Kent A. Griffith
No Relationships to Disclose
 
Bruce Shih-Li Lin
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Exelixis; Pfizer; QED Therapeutics
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Merck (Inst); Nucana (Inst); Sillajen (Inst); Zymeworks (Inst)
 
Heloisa P. Soares
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Exelixis; Ipsen; QED Therapeutics; TerSera
 
Sreenivasa R Chandana
Consulting or Advisory Role - Amgen; AstraZeneca; Dicephera Pharmaceuticals, Inc.; E.R. Squibb Sons, LLC; Johnson & Johnson/Janssen; Lilly
Speakers' Bureau - Amgen; Eisai; IPSEN; JNJ; Novartis
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); BMS (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Formation Biologics (Inst); Forty Seven (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Thomas Enzler
No Relationships to Disclose
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Seagen